Novel Peptides as Selective IL-23 Receptor Antagonists

JP2025521647A5Pending Publication Date: 2026-05-22SANOFI SA(FR)
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
SANOFI SA(FR)
Filing Date
2023-06-29
Publication Date
2026-05-22

AI Technical Summary

Technical Problem

Existing peptide compounds for oral administration in treating inflammatory diseases like Crohn's disease have limited stability in the intestinal environment and do not effectively target the IL-23 pathway, leading to systemic side effects and reduced efficacy.

Method used

Development of macrocyclic lactam peptides with specific structural motifs that enhance stability against proteases, increase affinity for the IL-23 receptor, and inhibit IL-23 signaling, suitable for oral administration.

Benefits of technology

The peptides exhibit high affinity for the IL-23 receptor, providing potent anti-inflammatory effects with improved stability and reduced systemic side effects, making them suitable for treating intestinal inflammation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024003313000001
    Figure 2024003313000001
  • Figure 2024003313000002
    Figure 2024003313000002
  • Figure 2024003313000003
    Figure 2024003313000003
Patent Text Reader

Abstract

The present disclosure relates to, for example, peptide IL23 receptor antagonists, pharmaceutical compositions thereof and their medical use in the treatment of inflammatory bowel diseases such as Crohn's disease.
Need to check novelty before this filing date? Find Prior Art